2,218 reports of this reaction
2.5% of all DAPAGLIFLOZIN reports
#3 most reported adverse reaction
NAUSEA is the #3 most commonly reported adverse reaction for DAPAGLIFLOZIN, manufactured by AstraZeneca Pharmaceuticals LP. There are 2,218 FDA adverse event reports linking DAPAGLIFLOZIN to NAUSEA. This represents approximately 2.5% of all 89,435 adverse event reports for this drug.
Patients taking DAPAGLIFLOZIN who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is a less commonly reported adverse event for DAPAGLIFLOZIN, but still significant enough to appear in the safety profile.
In addition to nausea, the following adverse reactions have been reported for DAPAGLIFLOZIN:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 2,218 FDA reports for DAPAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 2.5% of all adverse event reports for DAPAGLIFLOZIN, making it one of the most commonly reported side effect.
If you experience nausea while taking DAPAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.